ArticleRheumatology (Oxford, England)2025
Elevated DAS28, CDAI, RAPID3 and five of seven RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQ.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Fibromyalgia in patients with idiopathic inflammatory myopathies: prevalence, associated factors, and relationship with patient outcomes and health care utilization.Clinical rheumatology · 2026Article
- RAPID3 disease activity trajectory among patients with rheumatoid arthritis new to specialty pharmacy medications.Journal of managed care & specialty pharmacy · 2026Article
- Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Computational approaches to multimodal data integration in rheumatoid arthritis: from data landscape to clinical translation.Briefings in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo analyze three MDHAQ (Multidimensional Health Assessment Questionnaire) patient distress screening indices, MAS2 (MDHAQ anxiety screen), MDS2 (MDHAQ depression screen) and FAST3F (fibromyalgia assessment screening tool), for potential associations with elevated rheumatoid arthritis (RA) activity/severity indices in routine care patients.
methodsA cross-sectional database included the seven RA core data set measures and three MDHAQ patient distress indices. Mean individual measures and five indices-DAS28-ESR (disease activity score 28-erythrocyte sedimentation rate), DAS28-CRP (DAS28-C-reactive protein), SDAI (simplified disease activity index), CDAI (clinical disease activity index), and RAPID3 (routine assessment of patient index data),-and the number of patients classified into high, moderate, low or remission, were computed according to positive or negative MDHAQ screening indices, including in patients with 0,1 vs ≥2 swollen joints, analyzed using t tests and chi2 tests.
resultsAmong 173 patients, positive screening was seen in 37% for MAS2, 27% for MDS2, 31% for FAST3F and 45% for at least one of these three MDHAQ screening indices. All five RA indices and five of seven core data set measures were elevated significantly (P-value < 0.01), other than swollen joint count (SJC), ESR and CRP, in MAS2, MDS2 and/or FAST3F positive patients, generally to a higher activity/severity category. In the 27-41% of all patients with 0 or 1 SJC but moderate/high RA index activity/severity, a positive MDHAQ anxiety, depression and/or fibromyalgia screen was seen in 54-100%.
conclusionFive RA indices and five of seven individual core data set measures are elevated significantly in patients who screen positive for anxiety, depression and/or fibromyalgia on MDHAQ indices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.